Validation of the new consensus criteria for the diagnosis of corticobasal degeneration
| Autor: | Alexander, S. K., Rittman, T., Xuereb, J. H., Bak, T. H., Hodges, J. R., James Rowe |
|---|---|
| Předmět: |
Male
Consensus tau Proteins Tissue Banks Neuropsychological Tests digestive system Basal Ganglia Diagnosis Differential Basal Ganglia Diseases Humans Neurodegeneration Neuropathology Aged Neurologic Examination Brain Reproducibility of Results Neurodegenerative Diseases AD FRONTOTEMPORAL DEMENTIA United Kingdom digestive system diseases Corticobasal Degeneration surgical procedures operative PET Dementia Female Supranuclear Palsy Progressive Alzheimer'S Disease Biomarkers |
| Zdroj: | Scopus-Elsevier Alexander, S K, Rittman, T, Xuereb, J H, Bak, T H, Hodges, J R & Rowe, J B 2014, ' Validation of the new consensus criteria for the diagnosis of corticobasal degeneration ', Journal of Neurology, Neurosurgery & Psychiatry, vol. 85, no. 8, pp. 923-927 . https://doi.org/10.1136/jnnp-2013-307035 Journal of Neurology, Neurosurgery, and Psychiatry |
| DOI: | 10.1136/jnnp-2013-307035 |
| Popis: | Background Corticobasal degeneration (CBD) is a complex neurodegenerative disorder. Accurate diagnosis is increasingly important, with the advent of clinical trials of drugs aimed at modifying the underlying tau pathology. CBD often presents with a 'corticobasal syndrome' including impairments of movement and cognition. However, patients with similar corticobasal syndromes can have neurodegenerative pathologies that are not CBD. In addition, patients with CBD may present with aphasia or behavioural change. The clinical diversity of CBD and mimicry by non-CBD pathologies hinders accurate diagnosis.Methods We applied the new consensus criteria of Armstrong and colleagues et al(1) to a cohort of patients with detailed longitudinal clinical evaluation and neuropathology.Results In patients with pathologically confirmed CBD, accuracy of diagnosis was similar under the new and previous criteria: 9/19 (47%) met criteria for probable CBD at presentation, 13/19 (68%) at last clinical assessment. Patients with a corticobasal syndrome but without CBD pathology all (14/14) met the new diagnostic criteria of probable or possible CBD, demonstrating that the new criteria lacks the necessary specificity for an accurate ante mortem clinical diagnosis of CBD. None of the clinical features used in the new criteria were more common in the patients with CBD pathology (n=19) than without (n=14).Conclusions The Armstrong criteria usefully broadens the recognised clinical phenotype of CBD but does not sufficiently improve the specificity of diagnosis to increase the power of clinical trials or targeted applications of tau-based disease-modifying therapies. Further work is required to show whether biomarkers could be more effective than clinical signs in the diagnosis of CBD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|